

Drug Action in CNS is different

not easy to measure scientifically

special significance to us as humans (some we use regularly for non-medical purposes: caffeine, alcohol, nicotine)

and they affect the way we "feel" - not easy to measure scientifically

CNS is complicated! The human brain ~1.4kg, contains 85 billion neurons

These are roughly the

5 in telencephalon (cerebral cortex)

70 in cerebellum

<1 in brainstem / spinal cord

Each neuron receives (on average, but varies widely) 7000 synapses

about 500,000 billion synapses in the brain (mostly chemical synapses, can have electrical too!)

Type	Eg	Target	Main role
Amino Acids	Excitation Glutamate Inhibition GABA	ligand-gated ion channels GPCRs	fast / slow excitation and inhibition
Catecholamines	Noradrenaline Dopamine ACh	GPCR	fast / slow transmission and modulation
Peptides	Substance P NPY Vasoactive intestinal polypeptide	GPCR	modulation
Lipids / Steroids	Endocannabinoids Androgen / Estrogen	GPCR and Nuclear and membrane receptors	modulation and pleiotropic
Small molecules	Nitric oxide (NO) Carbon monoxide	multiple targets action of a distance	modulation



definitions

- EPSP: ~~excitation~~ post-synaptic excitatory potential (EPSP)

- IPSP: ~~inhibit~~ inhibitory

modulator - used to be an effect which did not give rise to excitation / inhibition, but "affected their effectiveness" - amplification / reduction of other activity - but now includes up / down regulation of transmitter release, action outside synapses (NO and GABA) merges into long term neurotrophic effects

constitutive receptor activation: some receptors are in an active state, even in the absence of a ligand, ~~proportion~~ proportion is highly variable, dependent upon receptor type, location

↓
can be induced in certain circumstances

and pathophysiology

Inhibitory amino acids: glycine

- high concentration in spinal cord
- as neurotransmitter, role is distinctly different from action on NMDA receptors
- transporter proteins for reuptake - Gly_{T1} (cerebrates throughout CNS)
Gly_{T2} (spinal cord)
- synthesised in the body from serine, though also available in the diet
- 5-subunit pentameric receptors

Muscle contraction under voluntary control

↳ the Renshaw cell provides collateral / recurrent inhibition,
driven by axon collaterals from the Ia motor neurons

↳ Renshaw cells prevent over-activity in contracting muscle and also over-relaxation in antagonist muscle

agonist - glycine

antagonist - strychnine

location - spinal cord (Renshaw cells)

Actions / uses: uptake inhibition - potential to treat pain,
Parkinson's disease
epilepsy

Catecholamines

- dopamine (Parkinson's, Schizophrenia)
- noradrenaline
- serotonin (5-hydroxytryptamine) (depression, pain management)

general properties

- long projection systems
- modulatory role over multiple brain pathways and circuits
- but some specific eg: dopamine in motor systems works along with ACh
- multiple receptor types and sub-types
- good site for drug therapy
- major serotonergic pathways arise in the Raphe nuclei

apple: good source of catecholamine

Catecholamine ~~is~~
oxidise → apple turn brown

* tyrosine restricted to enter the brain
by blood brain barrier (BBB)

DOPA is taken up by transporter in BBB better
compared to tyrosine, hence DOPA → Parkinson's
disease
treatment

* dopamine can inhibit
tyrosine hydroxylase
(end-product inhibition)



tyrosine
↓ tyrosine hydroxylase
DOPA (L-DOPA)
↓ DOPA decarboxylase
dopamine
↓ dopamine-β-hydroxylase
noradrenaline
↓ phenylethanolamine-N-methyltransferase
adrenaline

ACh Receptors

Type	Nicotinic	Muscarinic
	→ similar to AMPA → important in NMJ	→ important in CNS
Signal	↑ Na ⁺	Influences K ⁺ permeability
Effect	Excitatory	Mixed
	"FAST"	"SLOW"
	↳ Na ⁺ influx when channel open	

* 2 ACh required for nAChR activation

Muscarinic

- 5 subtypes mAChR₁₋₅ (GPCR)
- M₁, M₃, M₅ are excitatory through non-linear action of "M current"
- M₂, M₄ are inhibitory through actions of K⁺ and Ca²⁺ channels (hyperpolarisation)
(open) (close)

Nicotinic

- nAChR → ligand-gated to Na⁺, K⁺ and Ca²⁺ channels
- pentameric structure, homo / heteromeric, usually presynaptic (CNS), facilitating Glu release
though some specific postsynaptic sites also (NMJ)

↳ Muscarinic receptors probably most important i.e. mediate major functions, more widely spread

↳ nicotinic receptors have special role for humans - tobacco effects

↳ multiple drug actions on synthesis and breakdown of transmitter, actions on receptors

↳ wide profile of drug actions resulting from side-effects of other drugs

Structure of nAChR

- Heteropentamer of 4 related subunits ($\alpha, \beta, \gamma, \delta$) — always 2 α , 2 ACh needed for activation
- each subunit has a TM α -helix (the M2 helix)
- 5 M2 helices combine to form the pore
- each α -subunit contains a ACh binding site
- binding of ACh opens the receptor
- most ligand-gated ion channels have similar structure
- ACh induces a conformational change in the receptor, large hydrophobic residues are replaced by small polar residues (we charged)

ϵ - fetal form

δ - adult form

Preview from Notesale.co.uk
Page 14 of 80

Pharmacological treatments

- L-DOPA (levodopa), substrate for DOPA decarboxylase, can ↑ CNS dopamine levels
- can cause peripheral effects so given with carbidopa / benserazide to block peripheral DOPA decarboxylase (doesn't cross BBB)
- can also be combined w/ entacapone / tolcapone, COMT inhibitors, working both peripherally to prevent L-DOPA metabolism, centrally to prevent dopamine metabolism

Unwanted side effects

- L-DOPA can cause "involuntary ~~but~~ writhing movements" or dyskinesia.
Seen in majority of patients within 2 years of initiation
- rapid changes in clinical status - the "on-off" effect, when symptoms like hypokinesia suddenly reappear for short periods - possibly due to short $t_{1/2}$ of DOPA and the loss of dopamine stores
- nausea, can be treated w/ domperidone - itself a dopamine antagonist, but works via chemo-trigger zone of the BB interface and does NOT cross into the CNS
- postural hypotension
- psych psychological effects - schizophrenia-like symptoms (delusions and hallucinations)
more commonly confusion, insomnia, nightmares (24% of patients)

Dopamine agonists

- Bromocriptine and pergolide - orally active ergot derivatives
- use limited by side effects (mainly nausea / vomiting)
- pramipexole and ropinirole - more active at D₂ / D₃ receptors, don't have the levodopa "on-off" effect
- use limited by side-effects which include "compulsive behaviour" such as gambling and hyper-sexuality, through actions on dopamine-mediated reward circuits

Preview from Notesale.co.uk
Page 30 of 80

New Avenue

- 6-OHDA: relatively selective catecholaminergic neurotoxin
- taken up by the dopamine $\downarrow$ NA transporters
- selectivity for dopamine is achieved by pre-treating the subjects with desimipramine, a NA transporter blocker
- bilateral 6-OHDA lesion causes symmetrical body akinesia (slow movement)
- In mice expressing channelrhodopsin in direct pathway neurons, these effects can be counteracted by bilateral illumination of the striatum

Huntington's disease

- inherited (autosomal dominant) disorder, results in progressive brain degeneration
- 5-10 per 10,000 become obvious only in middle life
- results in dementia, but also severe motor symptoms - chorea: involuntary writhing movements which can be extremely debilitating. Onset occurs 15-20 years after onset
- probably due to $\downarrow$ local inhibition, resulting in $\uparrow$ dopaminergic activity
- results in early neural degeneration in the striatum, affecting cells in the indirect pathway
- removes an inhibitory influence on ~~the~~ GPe and STN (reduces its excitatory drive to sp.)
- results in $\downarrow$ inhibitory drive to the thalamus
- thalamo-cortical drive to motor areas $\uparrow$ (opposite of Parkinson's disease)

Pharmacological Treatments


- limited, at best
- tetraabenazine, an inhibitor of vesicular monoamine uptake (VMAT), $\downarrow$ DA levels
- chlorpromazine, a dopamine antagonist, usually used as an anti-psychotic
- haloperidol, clonazepam, risperidone and quetiapine can be used to suppress chorea in Huntington's disease. All are used labelled "unlicensed indication"

Preview from Notesale.co.uk
Page 32 of 80

PGE_2


Receptors	Presence in POA	Effect of (knock-out)
EP 1	Yes	attenuated pyresis
EP 2	NO	-
EP 3	Yes	no pyretic response
EP 4	Yes	??

Pyrexia, fever



T_b = body temp
 T_o = set point

Hyperthermia



Preview from Notesale.co.uk
 Page 37 of 80

Anti-Pyretic Actions

- thermostat raised by IL and PGs - Core temp. $\uparrow$
- Aspirin inhibit COX enzymes : $\downarrow$ PG production
 - thermostat back to normal
 - sweat & vasodilate to lose heat
 - restore core temp.
- will not decrease temperature in hyperthermia (not due to $\uparrow$ thermostat)
 - ↳ have to be treated using ice bath, cold pack...

Sensory (afferent) inputs

- Acute 'sharp' pain : Aδ-fibres
(myelinated, 5-30m/s)
- Aching dull pain : C-fibres
(not-myelinated, 1m/s)

from dorsal horn

Rexed's laminar pattern in spinal cord

Continues into ventral horn

Ascending pathways involved in pain

- 3 pathways - somatosensory : effective sensation - immediate reaction to "pain" (connections to cingulate cortex) + pain localisation
- spino reticular : emotional aspects & analgesia
 - spino mesencephalic : direct to PAG, initiating pain modulation system
 - cervicomedullary
 - spinothalamo

Descending pathways involved in pain

Body's own pain management system

- periaqueductal grey matter = PAG

- locus coeruleus = LC / AG (arousal centre of brain)

- nucleus raphe magnus = NRM

Opioids (not just opiates)

- compounds / drugs w morphine like actions

- these actions blocked by naloxone, an opioid antagonist

includes : Morphine (naturally occurring - opium extract)

Semisynthetic derivatives


Synthetic compounds

Endogenous neuropeptides

eg: endorphins, enkephalins, dynorphins (contains Tyr residue which fit onto the receptor)

- role in response to pain, released in response to pain, acupuncture / sport

Pain circuits



1) damage to tissue → nociceptor activity

Activators of PAG

AD

bradykinin, PG

nerve growth factor (NGF)

substance P, calcitonin-gene related peptide (CGRP)

Cortex : amygdala, insular cortex, hypothalamus

midbrain : PAG → Medulla : rostroventral medulla

Opioid

Opioid Receptors

- family of GPCRs, 3 subtypes have been cloned
- show 65% homology
- negatively linked to adenylate cyclase ($\downarrow$ cAMP)
- thereby regulate ion channels - open K^+ channels $\hookrightarrow$ hyperpolarisation

Traditional

Mu (μ)

Delta (δ)

Kappa (κ)

others (*ORL1)

* Actually an anti-opioid receptor,

nociceptin-orphanin FR receptor

New

MOPr

DOPr

KOPr

NDPr

subtypes exist for each receptor class

Mu opioid receptors (MOPr)

- subtypes 1, 2, 3 exist
- Act to open K^+ channels (hyperpolarisation)
- $\downarrow$ neuronal activity
- inhibit neurotransmitter release e.g. Ach, GABA, substance P
- responsible for most analgesic effect
- major side effects: respiratory depression, constipation, euphoria, sedation, dependence

(GIRK)
- G-protein-activated inwardly rectifying potassium channels
subunit, GIRK2

Delta opioid receptors

- subtypes 1 & 2 exist,
- act similarly to Mu receptors
- produces analgesia
- can be proconvulsant

Kappa opioid receptors

- subtypes 1, 2, 3 exist
- $\downarrow$ Ca^{2+} channel activity
- inhibit neurotransmitter release
- analgesia at the spinal level

- may elicit sedation, dysphoria / hallucinations - KOPr activity can be coupled to Mu antagonism

$\nearrow$ opposite of euphoria

preview from Notesale.co.uk
Page 39 of 80

Pharmacokinetics of General Anaesthesia

- we would like rapid induction and rapid recovery
- prefer to avoid stage 2
- prefer patient NOT to die in stage 4
- prefer to avoid side effects

Inhalation Anaesthetics

- Enter and leave body via the lungs
- metabolism generally unimportant for recovery
- pass from gas phase to blood, then to tissues

Blood-gas partition coefficient

- A measure of how well drug dissolves in blood
- determines rate of induction and recovery
- a low blood-gas partition coefficient gives rapid induction and recovery

Oil-gas partition coefficient

- High oil-partition coefficient confers high potency
- BUT lots of anaesthetics will dissolve in blood
- fat is poorly vascularised
- anaesthetics will take a long time to leave this tissue
- patient will have a slowly resolving "hangover"
- this will be worse the fatter the patient (and the more fat-soluble the drug)

GABA_A - halothane

NMDA - halothane

Two-pore K⁺ channels - halothane

preview from Notesale.co.uk
Page 46 of 80

Which is the best anti-psychotic?

- such drug do not exist
- patients respond individually
- Some patients ~~don't~~ do not respond to any drugs
- side effects may vary
- some patients find particular side effects hard to cope with
- Atypical drug frequently used as first line treatment : risperidone

Antipsychotic potency	daily dose
chlorpromazine	100mg
clozapine	300mg
haloperidol	3-5mg
promazine	2mg
risperidone	4mg
sulpiride	200mg
trifluoperazine	
trifluoperazine	10mg

* Potency varies widely, efficacy is very similar (w one exception)

↓
clozapine
↳ works better in patients
that resist other drugs

Antipsychotics


- 1st generation (typical) - very good at treating +ve symptoms, not -ve symptoms
- bad side effects
- 2nd (atypical) - very low risk of EPS
- slightly better at -ve symptoms
↳ sometimes can get drug-induced +ve symptoms

Typical

- butyrophenones
- phenothiazines
- thioxanthenes
- substituted benzamides
- diphenylbutyl-piperidines

amisulpride - atypical

- clozapine
- olanzapine
- quetiapine
- risperidone
- ~~amisulpride~~ aripiprazole



Preview from Notesale.co.uk
Page 56 of 80

Chlorpromazine

- The 1st effective antipsychotics (Group 1 Phenothiazine)
- Introduced 1952-1954
- "Largactil" Thiazine
- CPZE : standardisation
- side effects : very sedating, moderate extrapyramidal, neuroleptic malignant syndrome
muscarinic
galactorrhea
- derivatives : similar efficacy, differ in side effect profile

Haloperidol

- most commonly used typical
- 'Haldol'
- higher potency than chlorpromazine
- also used as an ~~anesthetic~~ anesthetic
- variety of formulations
- side effects : lower sedation, lower muscarinic, ↑ risk of EPS, restlessness, neuroleptic malignant syndrome

Risperidone

- atypical antipsychotic
- 'risperdal'
- improves the ~~if~~ negative symptoms
- oral formulation now out to ~~patent~~ patent so very cheap
- also available as I.M. and depot formulations
- side effects : moderate sedation, weight gain, galactorrhea, EPS at higher doses

Preview from Notesale.co.uk
Page 57 of 80
depot: oily injection into muscle

Quetiapine

- atypical
- 'seroquel'
- side effects
 - ↳ very sedating, causes drowsiness / tiredness
 - ↳ moderate muscarinic effects
 - ↳ moderate weight gain
 - ↳ moderate hypotension
 - ↳ no EPS, galactorrhea
- available in sustained formulation

Clozapine-induced agranulocytosis

loss of WBC (suppressed immune system ~1% patients)

↳ infection [treat w/ antibiotics]

↳ death [4-16% cases]

Clozapine monitoring

• often initiated as in-patient

• 3 days missed (flat over!)
of drug

• white blood cell count

• monitoring - ~~twice daily~~ (1 week)

- daily (1 week)

- weekly (18 weeks)

- biweekly (18 weeks)

- monthly thereafter

Antipsychotic compliance

• the best medication is of little use unless it is taken

• reasons for non-compliance

↳ lack of belief in illness

↳ side effects

↳ disorganised life style

Preview from Notesale.co.uk
Page 59 of 80

Formulations

1) oral (community)

2) intramuscular injection - psychiatry emergency situation
- involuntary

3) intramuscular depot injection - involuntary
- disorganised patients

- 2/4 weekly injection

• eliminates covert non-compliance

• sometimes effect delayed

↳ risperidone (Risperdal Consta)

↳ pipotiazine (depot only)

↳ haloperidol

↳ aripiprazole

Non-drug therapies

- 30-40% patients don't benefit from drugs (genetic factors)
- Cognitive behavioural therapy (CBT) can be effective (can be combined w other drugs)
- electroconvulsive therapy (ECT)

Antidepressant Discontinuation Syndrome

- Flu-like symptoms, motor and cognitive disturbances when drug is stopped
- usually lasts 1-4 weeks
- particular problem w paroxetine and venlafaxine

need to taper dose gradually

ECT (producing seizure in brain without major motor effects) → due to pretreatment w muscle relaxants


Successful in 85% patients w well-defined major depression

Indications for ECT

- maybe suicidal
- failed to respond to drugs
- in a debilitating stupor

• suffer other psychotic illness (chance of adverse drug reactions)

The oppositional tolerance model




Treatment of Bipolar Disorder

- Mood-stabilising drugs
- lithium
- anticonvulsants: lamotrigine, valproate, carbamazepine
- sometimes give antipsychotics as adjunct medication eg risperidone
- occasionally give AD drugs alongside mood stabilisers (may precipitate mania)

Lithium: a mystery

* narrow therapeutic window (need to monitor plasma levels)
lots of adverse effect



Animal Models of Depression (subject an animal to repeated pain which cannot be escaped)

- chronic stress (pain) → learned helplessness
↳ animal does NOT try to escape from pain

Forced Swim Test: normal mouse swim to safety
depression mouse give up
suspend mouse/tail to induce pain → depression